Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 3Diagnosis: Leukemia/MDS, Hodgkin's LymphomaNCT ID: NCT01597778
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-188
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can be used for HCT. This study will compare the effectiveness of two new types of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow donated from family members with only partially matched bone marrow; and, one that uses two partially matched cord blood units.
Conducting Institutions: Children's Hospital Boston, Dana-Farber Cancer Institute
Overall PI: Corey Cutler, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Christine Duncan, MD,
Dana-Farber Cancer InstituteKaren Ballen, MD,
Massachusetts General Hospital
Contacts: Dana-Farber Cancer Institute:
email@example.comMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100